Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1994 Nov;70(5):886–892. doi: 10.1038/bjc.1994.415

Effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonists on the growth of human small-cell and non-small-cell lung carcinomas in nude mice.

J Pinski 1, A V Schally 1, G Halmos 1, K Szepeshazi 1, K Groot 1, K O'Byrne 1, R Z Cai 1
PMCID: PMC2033546  PMID: 7947094

Abstract

We investigated the effects of our synthetic bombesin/gastrin-releasing peptide (GRP) antagonists and somatostatin analogue RC-160 on the growth of human small-cell lung carcinoma (SCLC) and non-small-cell lung carcinoma (non-SCLC) lines in nude mice. Athymic nude mice bearing xenografts of the SCLC NCl-H69 line or non-SCLC NCl-H157 line were treated for 5 and 4 weeks, respectively, with somatostatin analogue RC-160 or various bombesin/GRP antagonists. RC-160, administered s.c. peritumorally at a dose of 100 micrograms per animal per day, inhibited the growth of H69 SCLC xenografts as shown by more than 70% reduction in tumour volumes and weights, as compared with the control group. Bombesin/GRP antagonists, RC-3440, RC-3095 and RC-3950-II, given s.c. peritumorally at a dose of 20 micrograms per animal per day, also inhibited the growth of H69 SCLC tumours. RC-3950-II had the greatest inhibitory effect and decreased tumour volume and weights by more than 80%. The growth of H-157 non-SCLC xenografts was significantly reduced by treatment with RC-160, but not with bombesin/GRP antagonist RC-3095. In mice bearing either tumour model, administration of RC-160 significantly decreased serum growth hormone and gastrin levels. Specific high-affinity receptors for bombesin and somatostatin were found on membranes of SCLC H69 tumours, but not on non-SCLC H157 tumours. Receptor analyses demonstrated high-affinity binding sites for epidermal growth factor (EGF) and insulin-like growth factor I (IGF-I) on the membranes of H69 and H157 tumours. EGF receptors were down-regulated on H69 tumours after treatment with RC-160 and bombesin/GRP antagonists. The concentration of binding sites for EGF and IGF-I on the H157 tumours was decreased after treatment with RC-160, but bombesin/GRP antagonist RC-3095 had no effect. These results demonstrate that bombesin/GRP antagonists inhibit the growth of H-69 SCLC, but not of H-157 non-SCLC xenografts in nude mice, whereas somatostatin analogue RC-160 is effective in both tumour models. This raises the possibility that these peptide analogues could be used selectively in the treatment of various subclasses of lung cancer.

Full text

PDF
886

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alexander R. W., Upp J. R., Jr, Poston G. J., Gupta V., Townsend C. M., Jr, Thompson J. C. Effects of bombesin on growth of human small cell lung carcinoma in vivo. Cancer Res. 1988 Mar 15;48(6):1439–1441. [PubMed] [Google Scholar]
  2. Bajusz S., Csernus V. J., Janaky T., Bokser L., Fekete M., Schally A. V. New antagonists of LHRH. II. Inhibition and potentiation of LHRH by closely related analogues. Int J Pept Protein Res. 1988 Dec;32(6):425–435. doi: 10.1111/j.1399-3011.1988.tb01373.x. [DOI] [PubMed] [Google Scholar]
  3. Beattie C. W., Hansen N. W., Thomas P. A. Steroid receptors in human lung cancer. Cancer Res. 1985 Sep;45(9):4206–4214. [PubMed] [Google Scholar]
  4. Bogden A. E., Taylor J. E., Moreau J. P., Coy D. H., LePage D. J. Response of human lung tumor xenografts to treatment with a somatostatin analogue (Somatuline). Cancer Res. 1990 Jul 15;50(14):4360–4365. [PubMed] [Google Scholar]
  5. Boring C. C., Squires T. S., Tong T. Cancer statistics, 1992. CA Cancer J Clin. 1992 Jan-Feb;42(1):19–38. doi: 10.3322/canjclin.42.1.19. [DOI] [PubMed] [Google Scholar]
  6. Cagle P. T., Mody D. R., Schwartz M. R. Estrogen and progesterone receptors in bronchogenic carcinoma. Cancer Res. 1990 Oct 15;50(20):6632–6635. [PubMed] [Google Scholar]
  7. Cai R. Z., Radulovic S., Pinski J., Nagy A., Redding T. W., Olsen D. B., Schally A. V. Pseudononapeptide bombesin antagonists containing C-terminal Trp or Tpi. Peptides. 1992 Mar-Apr;13(2):267–271. doi: 10.1016/0196-9781(92)90107-e. [DOI] [PubMed] [Google Scholar]
  8. Cai R. Z., Szoke B., Lu R., Fu D., Redding T. W., Schally A. V. Synthesis and biological activity of highly potent octapeptide analogs of somatostatin. Proc Natl Acad Sci U S A. 1986 Mar;83(6):1896–1900. doi: 10.1073/pnas.83.6.1896. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Cardona C., Rabbitts P. H., Spindel E. R., Ghatei M. A., Bleehen N. M., Bloom S. R., Reeve J. G. Production of neuromedin B and neuromedin B gene expression in human lung tumor cell lines. Cancer Res. 1991 Oct 1;51(19):5205–5211. [PubMed] [Google Scholar]
  10. Carney D. N., Cuttitta F., Moody T. W., Minna J. D. Selective stimulation of small cell lung cancer clonal growth by bombesin and gastrin-releasing peptide. Cancer Res. 1987 Feb 1;47(3):821–825. [PubMed] [Google Scholar]
  11. Cuttitta F., Carney D. N., Mulshine J., Moody T. W., Fedorko J., Fischler A., Minna J. D. Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer. 1985 Aug 29-Sep 4Nature. 316(6031):823–826. doi: 10.1038/316823a0. [DOI] [PubMed] [Google Scholar]
  12. Damstrup L., Rygaard K., Spang-Thomsen M., Poulsen H. S. Expression of the epidermal growth factor receptor in human small cell lung cancer cell lines. Cancer Res. 1992 Jun 1;52(11):3089–3093. [PubMed] [Google Scholar]
  13. Halmos G., Rekasi Z., Szoke B., Schally A. V. Use of radioreceptor assay and cell superfusion system for in vitro screening of analogs of growth hormone-releasing hormone. Receptor. 1993 Summer;3(2):87–97. [PubMed] [Google Scholar]
  14. Langdon S., Sethi T., Ritchie A., Muir M., Smyth J., Rozengurt E. Broad spectrum neuropeptide antagonists inhibit the growth of small cell lung cancer in vivo. Cancer Res. 1992 Aug 15;52(16):4554–4557. [PubMed] [Google Scholar]
  15. Layton J. E., Scanlon D. B., Soveny C., Morstyn G. Effects of bombesin antagonists on the growth of small cell lung cancer cells in vitro. Cancer Res. 1988 Sep 1;48(17):4783–4789. [PubMed] [Google Scholar]
  16. Liebow C., Reilly C., Serrano M., Schally A. V. Somatostatin analogues inhibit growth of pancreatic cancer by stimulating tyrosine phosphatase. Proc Natl Acad Sci U S A. 1989 Mar;86(6):2003–2007. doi: 10.1073/pnas.86.6.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Macaulay V. M., Everard M. J., Teale J. D., Trott P. A., Van Wyk J. J., Smith I. E., Millar J. L. Autocrine function for insulin-like growth factor I in human small cell lung cancer cell lines and fresh tumor cells. Cancer Res. 1990 Apr 15;50(8):2511–2517. [PubMed] [Google Scholar]
  18. Macaulay V. M., Smith I. E., Everard M. J., Teale J. D., Reubi J. C., Millar J. L. Experimental and clinical studies with somatostatin analogue octreotide in small cell lung cancer. Br J Cancer. 1991 Sep;64(3):451–456. doi: 10.1038/bjc.1991.330. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Macauly V. M., Teale J. D., Everard M. J., Joshi G. P., Smith I. E., Millar J. L. Somatomedin-C/insulin-like growth factor-I is a mitogen for human small cell lung cancer. Br J Cancer. 1988 Jan;57(1):91–93. doi: 10.1038/bjc.1988.16. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Mahmoud S., Staley J., Taylor J., Bogden A., Moreau J. P., Coy D., Avis I., Cuttitta F., Mulshine J. L., Moody T. W. [Psi 13,14] bombesin analogues inhibit growth of small cell lung cancerin vitro and in vivo. Cancer Res. 1991 Apr 1;51(7):1798–1802. [PubMed] [Google Scholar]
  21. Minuto F., Del Monte P., Barreca A., Alama A., Cariola G., Giordano G. Evidence for autocrine mitogenic stimulation by somatomedin-C/insulin-like growth factor I on an established human lung cancer cell line. Cancer Res. 1988 Jul 1;48(13):3716–3719. [PubMed] [Google Scholar]
  22. Moody T. W., Cuttitta F. Growth factor and peptide receptors in small cell lung cancer. Life Sci. 1993;52(14):1161–1173. doi: 10.1016/0024-3205(93)90098-n. [DOI] [PubMed] [Google Scholar]
  23. Munson P. J., Rodbard D. Ligand: a versatile computerized approach for characterization of ligand-binding systems. Anal Biochem. 1980 Sep 1;107(1):220–239. doi: 10.1016/0003-2697(80)90515-1. [DOI] [PubMed] [Google Scholar]
  24. Noronha R. F., Goodall C. M. Enhancement by testosterone of dimethylnitrosamine carcinogenesis in lung, liver and kidney of inbred NZR/Gd female rats. Carcinogenesis. 1983;4(5):613–616. doi: 10.1093/carcin/4.5.613. [DOI] [PubMed] [Google Scholar]
  25. Pinski J., Halmos G., Yano T., Szepeshazi K., Qin Y., Ertl T., Schally A. V. Inhibition of growth of MKN45 human gastric-carcinoma xenografts in nude mice by treatment with bombesin/gastrin-releasing-peptide antagonist (RC-3095) and somatostatin analogue RC-160. Int J Cancer. 1994 May 15;57(4):574–580. doi: 10.1002/ijc.2910570422. [DOI] [PubMed] [Google Scholar]
  26. Pinski J., Reile H., Halmos G., Groot K., Schally A. V. Inhibitory effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer. Cancer Res. 1994 Jan 1;54(1):169–174. [PubMed] [Google Scholar]
  27. Rabiasz G. J., Langdon S. P., Bartlett J. M., Crew A. J., Miller E. P., Scott W. N., Smyth J. F., Miller W. R. Growth control by epidermal growth factor and transforming growth factor-alpha in human lung squamous carcinoma cells. Br J Cancer. 1992 Aug;66(2):254–259. doi: 10.1038/bjc.1992.253. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Radulovic S., Cai R. Z., Serfozo P., Groot K., Redding T. W., Pinski J., Schally A. V. Biological effects and receptor binding affinities of new pseudononapeptide bombesin/GRP receptor antagonists with N-terminal D-Trp or D-Tpi. Int J Pept Protein Res. 1991 Dec;38(6):593–600. doi: 10.1111/j.1399-3011.1991.tb01545.x. [DOI] [PubMed] [Google Scholar]
  29. Radulovic S., Miller G., Schally A. V. Inhibition of growth of HT-29 human colon cancer xenografts in nude mice by treatment with bombesin/gastrin releasing peptide antagonist (RC-3095). Cancer Res. 1991 Nov 1;51(21):6006–6009. [PubMed] [Google Scholar]
  30. Reubi J. C., Waser B., Sheppard M., Macaulay V. Somatostatin receptors are present in small-cell but not in non-small-cell primary lung carcinomas: relationship to EGF-receptors. Int J Cancer. 1990 Feb 15;45(2):269–274. doi: 10.1002/ijc.2910450211. [DOI] [PubMed] [Google Scholar]
  31. Schally A. V. Oncological applications of somatostatin analogues. Cancer Res. 1988 Dec 15;48(24 Pt 1):6977–6985. [PubMed] [Google Scholar]
  32. Sethi T., Rozengurt E. Multiple neuropeptides stimulate clonal growth of small cell lung cancer: effects of bradykinin, vasopressin, cholecystokinin, galanin, and neurotensin. Cancer Res. 1991 Jul 1;51(13):3621–3623. [PubMed] [Google Scholar]
  33. Siegfried J. M., Owens S. E. Response of primary human lung carcinomas to autocrine growth factors produced by a lung carcinoma cell line. Cancer Res. 1988 Sep 1;48(17):4976–4981. [PubMed] [Google Scholar]
  34. Sinha Y. N., Salocks C. B., Vanderlaan W. P. Prolactin and growth hormone levels in different inbred strains of mice: patterns in association with estrous cycle, time of day, and perphenazine stimulation. Endocrinology. 1975 Nov;97(5):1112–1122. doi: 10.1210/endo-97-5-1112. [DOI] [PubMed] [Google Scholar]
  35. Sondak V. K., Bertelsen C. A., Tanigawa N., Hildebrand-Zanki S. U., Morton D. L., Korn E. L., Kern D. H. Clinical correlations with chemosensitivities measured in a rapid thymidine incorporation assay. Cancer Res. 1984 Apr;44(4):1725–1728. [PubMed] [Google Scholar]
  36. Srkalovic G., Szende B., Redding T. W., Groot K., Schally A. V. Receptors for D-Trp6-luteinizing hormone-releasing hormone, somatostatin, and insulin-like growth factor I in MXT mouse mammary carcinoma. Proc Soc Exp Biol Med. 1989 Dec;192(3):209–218. doi: 10.3181/00379727-192-42987. [DOI] [PubMed] [Google Scholar]
  37. Staley J., Coy D., Taylor J. E., Kim S., Moody T. W. [Des-Met14]bombesin analogues function as small cell lung cancer bombesin receptor antagonists. Peptides. 1991 Jan-Feb;12(1):145–149. doi: 10.1016/0196-9781(91)90181-n. [DOI] [PubMed] [Google Scholar]
  38. Szepeshazi K., Schally A. V., Cai R. Z., Radulovic S., Milovanovic S., Szoke B. Inhibitory effect of bombesin/gastrin-releasing peptide antagonist RC-3095 and high dose of somatostatin analogue RC-160 on nitrosamine-induced pancreatic cancers in hamsters. Cancer Res. 1991 Nov 1;51(21):5980–5986. [PubMed] [Google Scholar]
  39. Szepeshazi K., Schally A. V., Halmos G., Groot K., Radulovic S. Growth inhibition of estrogen-dependent and estrogen-independent MXT mammary cancers in mice by the bombesin and gastrin-releasing peptide antagonist RC-3095. J Natl Cancer Inst. 1992 Dec 16;84(24):1915–1922. doi: 10.1093/jnci/84.24.1915. [DOI] [PubMed] [Google Scholar]
  40. Tateishi M., Ishida T., Mitsudomi T., Sugimachi K. Prognostic implication of transforming growth factor alpha in adenocarcinoma of the lung--an immunohistochemical study. Br J Cancer. 1991 Jan;63(1):130–133. doi: 10.1038/bjc.1991.26. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Taylor J. E., Moreau J. P., Baptiste L., Moody T. W. Octapeptide analogues of somatostatin inhibit the clonal growth and vasoactive intestinal peptide-stimulated cyclic AMP formation in human small cell lung cancer cells. Peptides. 1991 Jul-Aug;12(4):839–843. doi: 10.1016/0196-9781(91)90143-d. [DOI] [PubMed] [Google Scholar]
  42. Thomas F., Arvelo F., Antoine E., Jacrot M., Poupon M. F. Antitumoral activity of bombesin analogues on small cell lung cancer xenografts: relationship with bombesin receptor expression. Cancer Res. 1992 Sep 15;52(18):4872–4877. [PubMed] [Google Scholar]
  43. Veale D., Ashcroft T., Marsh C., Gibson G. J., Harris A. L. Epidermal growth factor receptors in non-small cell lung cancer. Br J Cancer. 1987 May;55(5):513–516. doi: 10.1038/bjc.1987.104. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Woll P. J., Rozengurt E. [D-Arg1,D-Phe5,D-Trp7,9,Leu11]substance P, a potent bombesin antagonist in murine Swiss 3T3 cells, inhibits the growth of human small cell lung cancer cells in vitro. Proc Natl Acad Sci U S A. 1988 Mar;85(6):1859–1863. doi: 10.1073/pnas.85.6.1859. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Zachary I., Sinnett-Smith J. W., Rozengurt E. Early events elicited by bombesin and structurally related peptides in quiescent Swiss 3T3 cells. I. Activation of protein kinase C and inhibition of epidermal growth factor binding. J Cell Biol. 1986 Jun;102(6):2211–2222. doi: 10.1083/jcb.102.6.2211. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES